Written Question·Department of Health and Social Care·UIN 49801
Abiraterone
Tabled: 1 May 2025
Answered: 12 May 2025
Question
Liz Jarvis
Liberal Democrat — Eastleigh
To ask the Secretary of State for Health and Social Care, whether the NHS plans to fund abiraterone for patients with high-risk non-metastatic prostate cancer.
Answer
Karin SmythThe Department has had no such discussions. Abiraterone does not have a marketing authorisation for use in the treatment of high-risk, non-metastatic prostate cancer and has not been evaluated for that indication by the National Institute for Health and C...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 49801) →